Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06917508 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
A Phase 1 study of RSV Infection and Drug-Drug Interaction, sponsored by Enanta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06917508: Completed Phase 1 study of RSV Infection and Drug-Drug Interaction, sponsored by Enanta Pharmaceuticals.
NCT06917508 is a Phase 1 study of RSV Infection and Drug-Drug Interaction that has completed, run by Enanta Pharmaceuticals. The registered enrollment target is 24 participants, below the 744-participant average among 8 other RSV Infection trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06917508, a Phase 1 study of RSV Infection and Drug-Drug Interaction, has completed, sponsored by Enanta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim of this study is to assess the effect of EDP-323 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy adult participants.
Conditions Studied
Interventions
- DRUG Midazolam
- DRUG Rosuvastatin
- DRUG Caffeine
- DRUG EDP-323
Study Locations (1)
Texas
- ICON, plc - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2025-06-13 |
| Phase | Phase 1 |
What the finished NCT06917508 record still lists
NCT06917508 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 744-participant average among 8 other RSV Infection trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with RSV Infection appearing as the primary indexed condition, and to 4 interventions - of which Midazolam is the first listed.
NCT06917508 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06917508 about?
NCT06917508 is a clinical study titled "A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants". The primary aim of this study is to assess the effect of EDP-323 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy adult participants.
What is the current status of trial NCT06917508?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-03-13. Estimated completion is 2025-06-13.
What conditions does trial NCT06917508 study?
This clinical trial studies the following conditions: RSV Infection, Drug-Drug Interaction.
What interventions are being tested in trial NCT06917508?
The interventions under investigation include: Midazolam (DRUG), Rosuvastatin (DRUG), Caffeine (DRUG), EDP-323 (DRUG).
Who is sponsoring clinical trial NCT06917508?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06917508 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for RSV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06917508's enrollment target sits among peer trials
24 9th of 8 the lowest of 8 other RSV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other RSV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
RECRUITING · Phase 1
-
A Study of EDP-323 in Healthy Subjects
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
COMPLETED · Phase 1
-
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
RECRUITING · Phase 3
-
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
RECRUITING
-
SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI